Biotech Showcase 2015 EBD Group Demy-Colton Image Map
Email this page Share this on LinkedIn Share this on Twitter

Biotech Showcase™ 2015 Press Releases

November 18, 2014Seventh Annual Biotech Showcase™ to be held in San Francisco January 12–14, 2015-- Record number of Life Science Investor meetings expected
The seventh annual Biotech Showcase investor conference will be held January 12–14, 2015 in San Francisco, CA at Parc 55 Wyndham San Francisco - Union Square. The event brings executive-level delegates representing top public and private investment firms with the goal to meet management teams of biotechnology and life science companies, including therapeutic companies, sp...  more ►

partnering360® Blog

December 17, 2014 Key incentives for doing business in China: Interview with Dan Zhang of Fountain Medical Development Ltd. You hear it a lot: China is the next big thing for life science companies, and any company interested in establishing a presence in China would be tapping into a lucrative, growing market. And it’s true: China is now the world’s second largest healthcare market and is on track to be the largest... more ►

December 11, 2014 Cancer immunotherapies and nano-based delivery approaches sure to be hot topics in 2015 A recent article published in the November 26, 2014 issue of Frontiers In Chemistry magazine discussed the performance and toxicity of various cancer immunotherapies, specifically monoclonal antibodies, immune adjuvants, vaccines and cell-based treatments, their differing delivery methods, and the... more ►

December 8, 2014 Partnerships are powerful in moving from apps to medical devices According to PricewaterhouseCooper, one of the top trends to keep an eye on next year in the healthcare field is the evolving role of medical apps moving to medical devices.  Next year, the FDA is set to review hundreds of apps.  But PWC points out that even though they’ve been reviewing... more ►

December 2, 2014 The complexity of immuno-oncology trials The value of developing an immunotherapy has grown over the past few years – as science and technology has developed far enough to help the immune system better recognize cancer cells as an abnormality within the human body.  The potential of this cancer treatment is huge as it would allow... more ►

December 1, 2014 More good news for private biotechs Guest post by Sara Jane Demy, CEO, Demy-Colton Life Science Advisors Polaris Partners joins the parade of new biotech funds launched in 2014 with a USD 450 million fund which exceeds the USD 400 million number they filed with the SEC last summer. Polaris joins Arch, Venrock, Versant and Sofinnova,... more ►

partnering360:Insight Latest headlines from partnering360:Insight

December 9, 2014 Interview with Dan Zhang, Foundation Medical Development partneringNEWS recently spoke with Dan Zhang, CEO of Fountain Medical Development, a CRO based mainly in China, but also with offices in the US, Taiwan, Hong Kong and South Korea. With China being the second largest healthcare market in the world, Zhang talks about the incentives for global companies to do business in China, and the ways in which FMD facilitates that. more ►

November 11, 2014 Bayer committed to Open Innovation and Collaborators The Head of Global Drug Discovery at Bayer HealthCare and a Member of the Executive Committee, Andreas Busch described the strategy underlying partnering efforts that he said have delivered a very significant value to patients as well as to shareholders. more ►

November 11, 2014 Merck Serono embraces partnering in all its forms Executive VP and Head of Global Research and Development at Merck Serono, Luciano Rossetti is also a Member of the Executive Committee who joined the company in late July this year. He offered to share with the audience a perspective from what he called a brief tenure. more ►

November 11, 2014 European biotech poised for acceleration David Loew is Senior VP for Commercial Operations in Europe at Sanofi. Rather than focusing on the company, Loew turned the spotlight on a wider concern for promoting a stronger environment for biotechs and start-ups in Europe. more ►

November 11, 2014 Transformational deals that shaped the industry in 2014 Led by moderator David Stubbs, the Managing Director for Inverness Advisors, the goal for the panel was to provide insights for transformational deals of the past year. The session was led off by a truly transformational deal that saw the USD 14.2 billion divestiture by Merck of its consumer healthcare business to Bayer HealthCare in May, 2014. The deal makes Bayer the second-biggest over-the-counter drug maker behind Johnson & Johnson. more ►

Arrow Up

See more upcoming conferences ►

EBD Group's Family of Events

© 2009–2014 EBD Group, Inc.
Privacy Policy
Terms of Use
Biotech Showcase 2015 EBD Group Demy-Colton Image Map